The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer
-
Narrated by:
-
By:
In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including:
- Rationale for targeting B7-H3
- Overview of the structure of antibody-drug conjugates (ADCs)
- Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLC
- Data from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLC
- An overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLC
- Early phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093
Program faculty:
Lauren Byers, MD
Professor and Thoracic Section Chief
Department of Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
Houston, Texas
Christine L. Hann, MD, PhD
Associate Professor of Oncology
Director, Small Cell Lung Cancer Therapeutics
Johns Hopkins University School of Medicine
Baltimore, Maryland
No reviews yet